Closed and Current Studies: Local Recent Clinical Trials held at MIRC


MIRC Clinical Research to Date



Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-412-2055

Title: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection


Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-366-1992

Title: A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co infected Subjects who Switch to Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) prior to LDV/SOF HCV Treatment


Sponsor: ViiV Healthcare  Protocol: GSK204861

Title: A Phase III, randomized, double-blind, multicentre, parallel group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults


Sponsor: CytoDyn, Inc.  Protocol: PRO 140_CD 02

Title: A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects


Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-292-1823

Title: A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects


Sponsor: Gilead Sciences, Inc.  Protocol: GS-US-292-1824

A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide(E/C/F/TAF) Fixed Dose Combination (FDC) inVirologically-Suppressed HIV-1 Infected Adult Subjects Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I


Sponsor: GlaxoSmithKline   Protocol: 201585

A Phase III, randomized, multicenter, parallel-group, non-inferiority, open-label study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long-acting rilpivirine from current INI- NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed


 Example of Recent Study:




Fort Pierce FL HIV & AIDs Treatment

Fort Pierce FL Hepatitis C Treatment, General ID & Clinical Trials

Call us at: (772) 595-9830
356 Midway Rd,
Fort Pierce, FL 34982